Apogee Therapeutics' Investigational Atopic Dermatitis Potential Shows Strong Tolerability, Extended Half-Life in Early Trial
1. APGE revealed promising Phase 1 results for APG990 with a 60-day half-life. 2. Data supports extended dosing intervals for effective treatment management. 3. No severe adverse events reported; study participants tolerated treatment well. 4. Plans to initiate further trials in atopic dermatitis by 2025. 5. APGE's financial position is strong, funding operations into 2028.